Login to Your Account

Lundbeck Gets Dibs on Proximagen CNS Products

By Catherine Shaffer

Friday, September 30, 2011
Proximagen Group plc, of London, partnered three of its developmental central nervous system (CNS) programs with H. Lundbeck A/S, of Valby, Denmark, in exchange for a stock purchase worth £10.3 million (US$16.2 million). The companies will work together to develop the three programs in the areas of epilepsy, pain and inflammatory disorders.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription